Short answer · Medically reviewed summary · Last updated: 2026-04-06
The prevalence of Myasthenia Gravis is estimated to be between 15 and 20 per 100,000 individuals globally, though these figures are dynamic and vary by region. Epidemiological Overview While Myasthenia Gravis is often classified as a rare disease, its prevalence appears to be rising, likely due to improved diagnostic tools and an aging global population. The annual incidence is estimated at approximately 0.3 to 2.8 per 100,000 people.
What is the prevalence of Myasthenia Gravis?
Prevalence of Myasthenia Gravis: how many people are affected worldwide, differences by sex and region, with sources.
The prevalence of Myasthenia Gravis is estimated to be between 15 and 20 per 100,000 individuals globally, though these figures are dynamic and vary by region.
Epidemiological Overview
While Myasthenia Gravis is often classified as a rare disease, its prevalence appears to be rising, likely due to improved diagnostic tools and an aging global population. The annual incidence is estimated at approximately 0.3 to 2.8 per 100,000 people. It is important to note that because symptoms can be fluctuating or mild, true prevalence may be higher than current estimates due to persistent underdiagnosis or misdiagnosis in clinical settings.
Demographics and Onset
Myasthenia Gravis displays a distinct bimodal age distribution. Early-onset cases typically occur in women under 40, while late-onset cases are more common in men over 60. Before the age of 50, women are affected more frequently than men; however, after age 50, the gender gap narrows, and the condition becomes more prevalent in men. While pediatric cases exist, they represent a smaller percentage of the total patient population compared to adult-onset cases.
Geographic and Community Insights
Data regarding ethnic variations in Myasthenia Gravis remain limited, though studies suggest slight differences in clinical presentation across populations. At DiseaseMaps.org, our community of 1,636 members provides a vital real-world perspective that complements traditional clinical data. By sharing lived experiences, our members help shed light on the diagnostic journey, which often involves significant delays that contribute to the challenges of capturing precise prevalence statistics. Whether you are newly diagnosed or a long-time warrior, understanding that Myasthenia Gravis is a heterogeneous condition helps validate the diverse experiences found within our community.
Medical Disclaimer: This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult with your neurologist or healthcare provider regarding your specific medical condition.
References
- NIH Genetic and Rare Diseases (GARD) Information Center
- Orphanet: The portal for rare diseases and orphan drugs
- Myasthenia Gravis Foundation of America (MGFA)
